EGFR positive

Doxorubicin (DOX) was efficiently encapsulated via temperature-controlled loading to obtain DOX@FTn-EGFRAfb with high protein recovery, pH-responsive drug release, and strong stability...In an orthotopic U87 glioma mouse model, DOX@FTn-EGFRAfb significantly inhibited tumor growth and prolonged survival without obvious systemic toxicity. This work presents a versatile protein-engineering strategy for dual-targeted glioblastoma drug delivery.

Disparities between Argentina's health subsystems significantly affect the BC stage at diagnosis and treatment timelines, influencing therapeutic pathways and associated costs. These findings highlight the need for targeted, system-level interventions. While further research is needed to confirm their long-term impact, such efforts may contribute to more equitable care and improved outcomes in LMICs.

Younger patients with breast cancer exhibited a higher frequency of high-grade tumors, although no differences were observed in RFS and DRFS. However, locoregional recurrence was more common among younger patients, especially HR-positive/HER2-negative breast cancer.

This case highlights a rare but severe complication of ABE treatment. While CDK4/6 inhibitors are widely used as first-line agents in advanced breast cancer due to their high efficacy and generally favorable side-effect profile, clinicians should remain vigilant for NE, which requires prompt intervention.

We discuss the case literature on the management of ophthalmic and eyelid metastases, including the role of radiotherapy. We outline the multi-disciplinary team (MDT) discussions and recommendations made in the present case, which ultimately found that the risks of radiation toxicity would outweigh the benefits. Adjuvant therapy with fulvestrant and palbociclib was recommended, with future consideration of a CDK 4/6 inhibitor in the event of metastatic recurrence.

HRD represents a reliable independent prognostic biomarker in HR+/HER2- breast cancer in this cohort, with an inverse association with TILs suggesting immune evasion. Its potential impact on prognosis and treatment requires further validation in prospective clinical trials.

Trastuzumab + pertuzumab (TP) was the most commonly used regimen in both neoadjuvant and adjuvant settings. The dual HER2 blockade regimens that were widely adopted in China for HR+/HER2+ early breast cancer have demonstrated effectiveness in improving pCR in routine clinical practice; a longer follow‑up is required to validate survival outcomes. None.

TARGIT-IORT is associated with excellent local control, very high survival rates, and a very low toxicity profile for low-risk early breast cancer, consistent with the TARGIT-A trial and should be offered to patients when suitable.

Commercially representative vepdegestrant tablets demonstrated bioequivalence with the pivotal phase 3 vepdegestrant tablets; all tablet formulations of vepdegestrant 200 mg were well tolerated.

Chemoimmunotherapy is the reference first-line regimen for biomarker-unselected advanced cholangiocarcinoma. Early comprehensive genomic profiling is essential to enable timely, matched targeted therapy and maximize population-level benefit.

Real-world data demonstrate that ODRS correlates with key pathological characteristics and can guide adjuvant therapy selection, independent of menopausal status or nodal involvement. This suggests that ODRS is useful in tailoring chemotherapy decisions in ER-positive/HER2-negative breast cancer.

We developed and validated a 10-PM model based on plasma metabolomics that accurately predicts short DFS in HR+/HER2- BC. This model outperforms conventional clinicopathological indicators, offering a specific, blood-based tool to stratify high-risk patients and guide individualized postoperative management.